Revolution Medicines trust plans 73K share sale
Revolution Medicines, Inc. (RVMD) is the issuer of common stock that an affiliate, the Kim Revocable Trust (with Lorence H. Kim as trustee), has filed to sell under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Revolution Medicines, Inc. (RVMD) is the issuer of common stock that an affiliate, the Kim Revocable Trust (with Lorence H. Kim as trustee), has filed to sell under Rule 144. The planned sale covers 73,090 shares of common stock through J.P. Morgan Securities LLC, listed on Nasdaq. These shares were acquired by a 50,000-share open‑market purchase on July 20, 2022 and by restricted stock unit (RSU) vesting in several tranches totaling 23,090 shares between December 15, 2022 and June 26, 2026. The notice states that RVMD had 214,336,418 shares outstanding as of August 31, 2026, providing context for the size of the planned sale relative to total shares.
Key Figures
Key Terms
Rule 144 regulatory
affiliate regulatory
RSU Vesting financial
aggregate market value financial
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for RVMD?
AI-generated analysis. How Rhea-AI works. Not financial advice.